FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants

A. Kanamaru, Y. Takemoto, E. Kakishita, H. Dohy, Y. Kodera, Y. Moriyama, A. Shibata, M. Kasai, S. Katoh, H. Saitoh, T. Matsuda, M. Hattori, Shinichiro Okamoto, S. Asano, A. Horiuchi, M. Harada, A. Hiraoka, T. Masaoka

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

A phase II study of the efficacy and safety of FK506, a new potent immunosuppressant, has been conducted in 49 patients with GVHD after allogeneic BMT. Eighteen patients with acute GVHD and 31 with chronic GVHD entered the study. FK506 was administered at an initial dose of 0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day to those whose GVHD had become uncontrollable with cyclosporin and/or other immunosuppressants. The response to FK506 was evaluated in 13 patients with acute and 26 with chronic GVHD. A marked response was observed in 5 and a good response in 2 of 13 patients with acute GVHD. For those with chronic GVHD, the response was marked in 2 patients, good in 10 and poor in 8. The most common adverse effects were renal toxicity (53.1%), followed by nausea and vomiting (30.6%) and a feeling of warmth (18.4%). There was a correlation between renal toxicity and whole blood levels of FK506. The dose should be adjusted to keep a trough level between 15 and 25 ng/ml, FK506 is promising in the treatment of both acute and chronic GVHD, even if it is intractable with other immunosuppressants, and may be most effective if administered early in the course of GVHD.

Original languageEnglish
Pages (from-to)885-889
Number of pages5
JournalBone Marrow Transplantation
Volume15
Issue number6
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Tacrolimus
Graft vs Host Disease
Immunosuppressive Agents
Cyclosporine
Kidney
Therapeutics
Nausea
Vomiting
Emotions
Safety

Keywords

  • FK506 treatment
  • GVHD

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Kanamaru, A., Takemoto, Y., Kakishita, E., Dohy, H., Kodera, Y., Moriyama, Y., ... Masaoka, T. (1995). FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Bone Marrow Transplantation, 15(6), 885-889.

FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. / Kanamaru, A.; Takemoto, Y.; Kakishita, E.; Dohy, H.; Kodera, Y.; Moriyama, Y.; Shibata, A.; Kasai, M.; Katoh, S.; Saitoh, H.; Matsuda, T.; Hattori, M.; Okamoto, Shinichiro; Asano, S.; Horiuchi, A.; Harada, M.; Hiraoka, A.; Masaoka, T.

In: Bone Marrow Transplantation, Vol. 15, No. 6, 1995, p. 885-889.

Research output: Contribution to journalArticle

Kanamaru, A, Takemoto, Y, Kakishita, E, Dohy, H, Kodera, Y, Moriyama, Y, Shibata, A, Kasai, M, Katoh, S, Saitoh, H, Matsuda, T, Hattori, M, Okamoto, S, Asano, S, Horiuchi, A, Harada, M, Hiraoka, A & Masaoka, T 1995, 'FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants', Bone Marrow Transplantation, vol. 15, no. 6, pp. 885-889.
Kanamaru, A. ; Takemoto, Y. ; Kakishita, E. ; Dohy, H. ; Kodera, Y. ; Moriyama, Y. ; Shibata, A. ; Kasai, M. ; Katoh, S. ; Saitoh, H. ; Matsuda, T. ; Hattori, M. ; Okamoto, Shinichiro ; Asano, S. ; Horiuchi, A. ; Harada, M. ; Hiraoka, A. ; Masaoka, T. / FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. In: Bone Marrow Transplantation. 1995 ; Vol. 15, No. 6. pp. 885-889.
@article{225a098a03d749d695fdba2435cc66d8,
title = "FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants",
abstract = "A phase II study of the efficacy and safety of FK506, a new potent immunosuppressant, has been conducted in 49 patients with GVHD after allogeneic BMT. Eighteen patients with acute GVHD and 31 with chronic GVHD entered the study. FK506 was administered at an initial dose of 0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day to those whose GVHD had become uncontrollable with cyclosporin and/or other immunosuppressants. The response to FK506 was evaluated in 13 patients with acute and 26 with chronic GVHD. A marked response was observed in 5 and a good response in 2 of 13 patients with acute GVHD. For those with chronic GVHD, the response was marked in 2 patients, good in 10 and poor in 8. The most common adverse effects were renal toxicity (53.1{\%}), followed by nausea and vomiting (30.6{\%}) and a feeling of warmth (18.4{\%}). There was a correlation between renal toxicity and whole blood levels of FK506. The dose should be adjusted to keep a trough level between 15 and 25 ng/ml, FK506 is promising in the treatment of both acute and chronic GVHD, even if it is intractable with other immunosuppressants, and may be most effective if administered early in the course of GVHD.",
keywords = "FK506 treatment, GVHD",
author = "A. Kanamaru and Y. Takemoto and E. Kakishita and H. Dohy and Y. Kodera and Y. Moriyama and A. Shibata and M. Kasai and S. Katoh and H. Saitoh and T. Matsuda and M. Hattori and Shinichiro Okamoto and S. Asano and A. Horiuchi and M. Harada and A. Hiraoka and T. Masaoka",
year = "1995",
language = "English",
volume = "15",
pages = "885--889",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants

AU - Kanamaru, A.

AU - Takemoto, Y.

AU - Kakishita, E.

AU - Dohy, H.

AU - Kodera, Y.

AU - Moriyama, Y.

AU - Shibata, A.

AU - Kasai, M.

AU - Katoh, S.

AU - Saitoh, H.

AU - Matsuda, T.

AU - Hattori, M.

AU - Okamoto, Shinichiro

AU - Asano, S.

AU - Horiuchi, A.

AU - Harada, M.

AU - Hiraoka, A.

AU - Masaoka, T.

PY - 1995

Y1 - 1995

N2 - A phase II study of the efficacy and safety of FK506, a new potent immunosuppressant, has been conducted in 49 patients with GVHD after allogeneic BMT. Eighteen patients with acute GVHD and 31 with chronic GVHD entered the study. FK506 was administered at an initial dose of 0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day to those whose GVHD had become uncontrollable with cyclosporin and/or other immunosuppressants. The response to FK506 was evaluated in 13 patients with acute and 26 with chronic GVHD. A marked response was observed in 5 and a good response in 2 of 13 patients with acute GVHD. For those with chronic GVHD, the response was marked in 2 patients, good in 10 and poor in 8. The most common adverse effects were renal toxicity (53.1%), followed by nausea and vomiting (30.6%) and a feeling of warmth (18.4%). There was a correlation between renal toxicity and whole blood levels of FK506. The dose should be adjusted to keep a trough level between 15 and 25 ng/ml, FK506 is promising in the treatment of both acute and chronic GVHD, even if it is intractable with other immunosuppressants, and may be most effective if administered early in the course of GVHD.

AB - A phase II study of the efficacy and safety of FK506, a new potent immunosuppressant, has been conducted in 49 patients with GVHD after allogeneic BMT. Eighteen patients with acute GVHD and 31 with chronic GVHD entered the study. FK506 was administered at an initial dose of 0.05 mg/kg i.v. or 0.15 mg/kg orally twice a day to those whose GVHD had become uncontrollable with cyclosporin and/or other immunosuppressants. The response to FK506 was evaluated in 13 patients with acute and 26 with chronic GVHD. A marked response was observed in 5 and a good response in 2 of 13 patients with acute GVHD. For those with chronic GVHD, the response was marked in 2 patients, good in 10 and poor in 8. The most common adverse effects were renal toxicity (53.1%), followed by nausea and vomiting (30.6%) and a feeling of warmth (18.4%). There was a correlation between renal toxicity and whole blood levels of FK506. The dose should be adjusted to keep a trough level between 15 and 25 ng/ml, FK506 is promising in the treatment of both acute and chronic GVHD, even if it is intractable with other immunosuppressants, and may be most effective if administered early in the course of GVHD.

KW - FK506 treatment

KW - GVHD

UR - http://www.scopus.com/inward/record.url?scp=0029062592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029062592&partnerID=8YFLogxK

M3 - Article

C2 - 7581086

AN - SCOPUS:0029062592

VL - 15

SP - 885

EP - 889

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -